[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371954-105":59,"doc-detail-371954-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","breast-cancer-therapy-by-small-molecule-reactivation-of-mutant-p53","Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53","","Tumor suppressor p53 maintains DNA stability and controls cell fate, but DNA damage and p53 regulation create a pathway from activation to cell-cycle arrest or apoptosis. p53 gene mutations disrupt this control and drive uncontrolled tumor growth, with 30–40% frequency in human breast cancers and 70–80% in triple-negative breast cancer. Many mutations cluster in the DNA-binding domain, producing accumulated mutant p53. Restoring mutant p53 to functional wild-type p53 using small-molecule activators, including PRIMA-1 and APR-246, is presented alongside mechanisms, in vitro effects, xenograft results, and a brief overview of p53-reactivation clinical trials and potentially low-toxicity plant-derived compounds.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/breast-cancer-therapy-by-small-molecule-reactivation-of-mutant-p53/371954/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/breast-cancer-therapy-by-small-molecule-reactivation-of-mutant-p53/371954.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is p53 important in preventing cancer progression?","Question",{"text":112,"@type":113},"Wild-type p53 maintains DNA stability and, after DNA damage, triggers cell-cycle arrest and provides time for repair; if damage is severe, it activates apoptosis to eliminate damaged cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do p53 mutations contribute to breast cancer and TNBC?",{"text":117,"@type":113},"Mutations impair tumor-suppressor function, leading to uncontrolled growth; p53 mutations occur in about 30–40% of breast cancers and rise to 70–80% in triple-negative breast cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do small molecules like PRIMA-1 and APR-246 play?",{"text":121,"@type":113},"Small-molecule activators aim to convert mutant p53 back to functional wild-type p53. The document describes PRIMA-1 reactivation effects and shows PRIMA-1 efficacy in arresting xenograft growth, while APR-246 is discussed as restoring tumor suppressor activity in TNBC cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371954,1791621949,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nBreast Cancer Therapy by Small-Molecule Reactivation of Mutant p53  \nSimon H. Slight  and Salman M. Hyder *  \nReceived: 15 October 2025  \nRevised: 24 November 2025  \nAccepted: 26 November 2025  \nPublished: 3 December 2025  \nCitation: Slight, S.H.; Hyder, S.M. Breast Cancer Therapy by  \nSmall-Molecule Reactivation of Mutant p53 . Curr. Oncol. 2025, 32, 684 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol32120684  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \nDepartment of Pathobiology and Integrative Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA  \n* [Correspondence: hyders@missouri.edu](Correspondence: hyders@missouri.edu)  \nSimple Summary  \nBreast cancer is the most common type of cancer in American women and, after lung cancer, is the deadliest form of the disease. About 30–40% of human breast cancers contain mutations in a gene that under normal situations prevents tumor growth. Termed tumor suppressor p53, this gene produces a protein that in its wild-type (unmutated) form maintains DNA stability and promotes apoptosis (cell death) of cancer cells. Unfortunately, mutant p53 is unable to prevent tumor growth, so efforts are underway to convert inactive mutant p53 into the active form of the protein. Several small molecules have been developed recently, which bind to mutant p53 and restore its anti-tumor activities. These molecules have been tested against a variety of human cancer cells, and in animal models of cancers that are hormone-dependent, as well as against triple-negative breast cancers, which are particularly aggressive and deadly. There is some evidence that certain naturally occurring, plant-derived compounds also have the capacity to convert mutant p53 into its active, anti-cancer form. Studies are ongoing to determine the effectiveness of such compounds, which are generally of low toxicity compared with currently employed chemotherapies and would provide many breast cancer sufferers with an alternative means of fighting the disease.  \nAbstract  \nTumor suppressor p53 is essential for maintaining DNA stability and preventing cancer. Under normal conditions, the p53 protein is either degraded or bound to a negative regulator, rendering it inactive, but when DNA damage occurs, p53 is activated, causing cell cycle arrest and allowing time for cellular repair. If, however, DNA damage is too severe, the cell undergoes apoptosis and is eliminated. Mutations in the p53 gene are linked to various types of cancer and are present in 30–40% of human breast cancers, leading to loss of tumor suppressor function and uncontrolled tumor growth. Moreover, in triple-negative breast cancer (TNBC), a particularly deadly form of the disease, the incidence of p53 mutations increases to 70–80% . Many p53 mutations occur in the DNA binding domain of the p53 gene, leading to accumulation of mutant p53 (mtp53) within the cell, and tumor development. Converting mtp53 back to its functional wild-type form (wtp53) is consequently a rational approach to preventing or even reversing tumor growth. Mechanisms of action of tumor suppressor p53 are widely discussed elsewhere; hence, we will focus on our own studies, using small molecule activators of mtp53 to combat breast cancer. We will show that specific small molecules, such as PRIMA-1 (p53 reactivation and induction of mass apoptosis), reactivate mtp53 in hormone-dependent human breast cancer cells. Furthermore, we will demonstrate the effectiveness of PRIMA-1 at arresting xenograft growth in an animal model and go on to show that the PRIMA-1 analog APR-246 effectively restores wtp53 tumor suppressor activity in TNBC cells. A bri","cbCaiqOemdvgTbj6","https://ap.wps.com/l/cbCaiqOemdvgTbj6","pdf",597730,11,"English","# Introduction\n## Tumor Suppressor p53","[{\"question\":\"Why is p53 important in preventing cancer progression?\",\"answer\":\"Wild-type p53 maintains DNA stability and, after DNA damage, triggers cell-cycle arrest and provides time for repair; if damage is severe, it activates apoptosis to eliminate damaged cells.\"},{\"question\":\"How do p53 mutations contribute to breast cancer and TNBC?\",\"answer\":\"Mutations impair tumor-suppressor function, leading to uncontrolled growth; p53 mutations occur in about 30–40% of breast cancers and rise to 70–80% in triple-negative breast cancer.\"},{\"question\":\"What role do small molecules like PRIMA-1 and APR-246 play?\",\"answer\":\"Small-molecule activators aim to convert mutant p53 back to functional wild-type p53. The document describes PRIMA-1 reactivation effects and shows PRIMA-1 efficacy in arresting xenograft growth, while APR-246 is discussed as restoring tumor suppressor activity in TNBC cells.\"}]","Breast Cancer Therapy by Small-Molecule Reactivation of Mutant p53 | PDF",1790193313,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4505c53d11b9102c11047f4efa959ba.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/174c8777126c17b652ecda3a56a0c903.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda41dc40c1a9b39f4935e05b989c80c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/586d2d64ea84ef39272c1b24c0bb90bc.webp",980,1385]